Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 4/5 core metricsOperating margin changed -5.4 percentage points from the prior annual period.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Operating margin compressed
Operating margin changed -5.4 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
- Free cash flow was negative
Latest reported free cash flow was -$180,000.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
- 4 filing risk checks flagged
Flagged areas: Earnings quality, Solvency & liquidity, Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +10.2% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Earnings quality
- Solvency & liquidity
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Gyre Pharmaceuticals$117M100.0%+10.2% yoy
Members sum to the consolidated $117M for this period.
- Gyre Pharmaceuticals$20M174.0%-9.2% yoy
- Gyre-$8.49M-73.9%+44.9% yoy
- All Other Segments-$19K-0.2%+850.0% yoy
Members sum to the consolidated $11.5M for this period.
- Gyre Pharmaceuticals$22.5M100.0%+2.1% yoy
- Gyre$00.0%no prior
- All Other Segments$00.0%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 4,121 US-listed filers · 796 in Materials| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $117M | 29thof 3,301 bottom third | 47thof 522 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 10.2% | 62ndof 3,135 middle third | 55thof 473 middle third |
Operating margin operating income ÷ revenue | 9.8% | 68thof 2,819 top third | 77thof 483 top third |
Net margin net income ÷ revenue | 8.5% | 67thof 3,263 top third | 78thof 518 top third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | -0.1% | 34thof 2,679 middle third | 55thof 433 middle third |
Return on equity net income ÷ stockholders' equity (positive equity only) | 9.3% | 64thof 3,577 middle third | 82ndof 701 top third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 6.1% | 32ndof 2,895 bottom third | 54thof 476 middle third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 97 days | 12thof 2,398 bottom third | 19thof 387 bottom third |
Cash conversion operating cash flow ÷ net income (net income > 0) | 0.1× | 11thof 2,181 bottom third | 12thof 190 bottom third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | 6.1% | 6thof 3,545 bottom third | 10thof 661 bottom third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | 19.4% | 29thof 3,029 bottom third | 36thof 582 middle third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 37 changed periods, 29 largest shown| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Depreciation and amortization DepreciationDepletionAndAmortization | quarter 2023-03-31 | $3K 10-Q 2023-05-15 | $276K 10-Q 2024-05-13 | +9100.0% | first · latest |
| Deferred revenue (current) ContractWithCustomerLiabilityCurrent | balance at 2025-12-31 | $14K 10-K 2026-03-13 | $1.18M 10-Q 2026-08-07 | +8357.1% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2023-03-31 | $178K 10-Q 2023-05-15 | $6.66M 10-Q 2024-05-13 | +3643.8% | first · latest |
| Net income NetIncomeLoss | quarter 2023-03-31 | $260K 10-Q 2023-05-15 | $4.22M 10-Q 2024-11-13 | +1521.9% | first · latest · 6 filings carry it |
| Stock-based compensation ShareBasedCompensation | fiscal year 2022-12-31 | $1.34M 10-K 2023-03-30 | $13.4M 10-K 2024-03-27 | +896.0% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2023-09-30 | -$1.62M 10-Q 2023-10-26 | $12.8M 10-Q 2024-11-13 | +886.4% | first · latest |
| Net income NetIncomeLoss | quarter 2023-09-30 | -$1.58M 10-Q 2023-10-26 | $7.51M 10-Q 2024-11-13 | +576.5% | first · latest |
| Depreciation and amortization DepreciationDepletionAndAmortization | fiscal year 2022-12-31 | $230K 10-K 2023-03-30 | $1.09M 10-K 2024-03-27 | +372.6% | first · latest |
| Stockholders' equity StockholdersEquity | balance at 2022-12-31 | -$21.7M 10-K 2023-03-30 | $42.5M 10-K 2024-03-27 | +296.1% | first · latest · 5 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2023-06-30 | -$2.54M 10-Q 2023-08-14 | $4.97M 10-Q 2024-08-13 | +295.6% | first · latest |
| Operating cash flow NetCashProvidedByUsedInOperatingActivities | quarter 2023-03-31 | -$6.22M 10-Q 2023-05-15 | $10.4M 10-Q 2024-05-13 | +267.6% | first · latest |
| Net income NetIncomeLoss | quarter 2023-06-30 | -$2.47M 10-Q 2023-08-14 | $3.77M 10-Q 2024-11-13 | +252.5% | first · latest · 4 filings carry it |
| Net income NetIncomeLoss | quarter 2025-06-30 | $1.58M 10-Q 2025-08-11 | -$2.24M 10-Q 2026-08-07 | -241.9% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | fiscal year 2022-12-31 | -$8.61M 10-K 2023-03-30 | $9.2M 10-K 2024-03-27 | +206.9% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2025-06-30 | $2.17M 10-Q 2025-08-11 | -$2.24M 10-Q 2026-08-07 | -203.2% | first · latest |
| Total assets Assets | balance at 2022-12-31 | $28.4M 10-K 2023-03-30 | $84.8M 10-K 2024-03-27 | +198.0% | first · latest · 5 filings carry it |
| Net income NetIncomeLoss | fiscal year 2022-12-31 | -$8.24M 10-K 2023-03-30 | $4.31M 10-K 2024-03-27 | +152.3% | first · latest |
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | fiscal year 2022-12-31 | 31,545,723 shares 10-K 2023-03-30 | 75,686,406 shares 10-K 2024-03-27 | +139.9% | first · latest |
| Operating cash flow NetCashProvidedByUsedInOperatingActivities | fiscal year 2022-12-31 | -$33.1M 10-K 2023-03-30 | $10.7M 10-K 2024-03-27 | +132.3% | first · latest |
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | quarter 2023-06-30 | 37,800,121 shares 10-Q 2023-08-14 | 78,904,324 shares 10-Q 2024-08-13 | +108.7% | first · latest |
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | quarter 2023-03-31 | 37,984,324 shares 10-Q 2023-05-15 | 78,921,366 shares 10-Q 2024-05-13 | +107.8% | first · latest |
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | quarter 2023-09-30 | 37,976,764 shares 10-Q 2023-10-26 | 78,904,324 shares 10-Q 2024-11-13 | +107.8% | first · latest |
| Net income NetIncomeLoss | quarter 2026-03-31 | -$9.86M 10-Q 2026-05-08 | -$18.6M 10-Q 2026-08-07 | -88.5% | first · latest |
| Basic shares WeightedAverageNumberOfSharesOutstandingBasic | quarter 2023-03-31 | 37,758,416 shares 10-Q 2023-05-15 | 63,588,119 shares 10-Q 2024-05-13 | +68.4% | first · latest |
| Basic shares WeightedAverageNumberOfSharesOutstandingBasic | quarter 2023-06-30 | 37,800,121 shares 10-Q 2023-08-14 | 63,588,119 shares 10-Q 2024-08-13 | +68.2% | first · latest |
| Basic shares WeightedAverageNumberOfSharesOutstandingBasic | quarter 2023-09-30 | 37,976,764 shares 10-Q 2023-10-26 | 63,588,119 shares 10-Q 2024-11-13 | +67.4% | first · latest |
| Stockholders' equity StockholdersEquity | balance at 2025-12-31 | $106M 10-K 2026-03-13 | $62.5M 10-Q 2026-08-07 | -41.1% | first · latest · 3 filings carry it |
| Cash CashAndCashEquivalentsAtCarryingValue | balance at 2025-12-31 | $37.1M 10-K 2026-03-13 | $49.2M 10-Q 2026-08-07 | +32.7% | first · latest · 3 filings carry it |
| Total assets Assets | balance at 2025-12-31 | $166M 10-K 2026-03-13 | $220M 10-Q 2026-08-07 | +32.3% | first · latest · 3 filings carry it |
1 share-count period re-presented for a stock split (2-for-1) are listed apart from restatements and not counted above.
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
Not available for GYRE yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.